Pumitamig alone or with other drugs for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called pumitamig, given alone or with other treatments, for people with advanced kidney cancer that has spread or cannot be removed. It aims to see if the drug is safe and if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced kidney cancer that has spread or cannot be treated with surgery or radiation.
- The cancer is mostly the clear cell type (for the main part of the study), but other types may be allowed in early stages.
- You have not had prior treatment for advanced kidney cancer, unless certain prior treatments are allowed.
- You have at least one measurable tumor (can be seen on scans).
- You do not have untreated brain metastases.
- You have not had certain heart, lung, or bleeding conditions recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—atorvastatin, axitinib, and toripalimab—to treat advanced clear-cell renal cell carcinoma (a common type of kidney cancer that has spread or cannot be surgically removed). The drugs work by targeting blood vessel growth and boosting the immune system to fight cancer cells.
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
This trial tests an experimental drug called pumitamig combined with standard chemotherapy for people with advanced pancreatic cancer that has spread and has not been treated yet. The goal is to see if this combination is safe and effective.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Hear when a new Advanced Renal Cell Carcinoma (RCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.